Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Excretion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    519 result(s) found for: Excretion. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005079-32 Sponsor Protocol Number: 00001 Start Date*: 2007-12-04
    Sponsor Name:Medical University of Vienna
    Full Title: Treatment of secondary renal amyloidosis A with the Intereleukin – 1 antagonist anakinra
    Medical condition: Renal Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000308-82 Sponsor Protocol Number: oxalate01 Start Date*: 2017-02-08
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial
    Medical condition: Urolithiasis and secondary hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000619-42 Sponsor Protocol Number: PI14/00638 Start Date*: 2015-05-05
    Sponsor Name:FIBICO
    Full Title: An open, Phase II, clinical trial to evaluate the effectiveness of decreased intestinal absorption of phosphorus in the progression of renal disease in patients with metabolic syndrome
    Medical condition: Chronic kidney disease and metabolic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015217-52 Sponsor Protocol Number: Uni-Koeln-1251 Start Date*: 2010-06-08
    Sponsor Name:University of Cologne
    Full Title: Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - Pilot trial on treatment of patients with primary hyperoxaluria type I with pyridoxal-phosphate
    Medical condition: In this study we will prospectively analyze the reduction of urinary oxalate excretion under the treatment with PLP in dosages of 5mg/kg/day up to 20 mg/kg/day and serum level response relationship...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10037671 Pyridoxine deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004352-33 Sponsor Protocol Number: ALLN-177-301 Start Date*: 2018-07-18
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study
    Medical condition: Enteric Hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002961-79 Sponsor Protocol Number: D1690C00049 Start Date*: 2017-05-23
    Sponsor Name:AstraZeneca AB
    Full Title: DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin treatment in Type 2 Diabetes Mellitus Patients with Either Preserved or Im...
    Medical condition: Type 2 Diabetes Mellitus patients with impaired renal function. Type 2 Diabetes Mellitus patients with normal renal function. Non-diabetic patients with impaired renal function.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002139-33 Sponsor Protocol Number: WADA2013sal Start Date*: 2014-09-26
    Sponsor Name:Bispebjerg University Hospital
    Full Title: Pharmacokinetics of inhaled salmeterol administrated in healthy trained males
    Medical condition: Pharmacokinetics of salmeterol regarding uptake and excretion
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005143-28 Sponsor Protocol Number: MED.RES.HOS.2006.03.LP Start Date*: 2006-12-06
    Sponsor Name:Medicinsk Forskning
    Full Title: Effects of HMG-CoA-reductase inhibition (atorvastatin) on renal sodium excretion, renal hemodynamics, tubular function and vasoactive hormones in healthy subjects under diet with normal and high so...
    Medical condition: Healthy volunteer trial
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000501-29 Sponsor Protocol Number: CRC-ER-1_2007 Start Date*: 2008-10-27
    Sponsor Name:University Hospital of Erlangen
    Full Title: Low grade albuminuria: reaching a new target for irbesartan
    Medical condition: low grade albuminuria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001580 Albuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-001152-35 Sponsor Protocol Number: UX003-CL201 Start Date*: 2013-08-02
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients with MPS 7
    Medical condition: Mucopolysaccharidosis type 7 (MPS 7, Sly syndrome)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006120-20 Sponsor Protocol Number: 31-06-2011 Start Date*: 2012-03-15
    Sponsor Name:University Medical Centre Ljubljana
    Full Title: Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial
    Medical condition: Proteinuria in kidney transplant recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002466-20 Sponsor Protocol Number: 4087 Start Date*: 2012-08-16
    Sponsor Name:Royal Liverpool And Broadgreen University Hospitals NHS Trust
    Full Title: An exploratory, randomised, 3-way crossover study to determine the effect of paracetamol on urinary cystine excretion in cystinuria
    Medical condition: Cystinuria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011778 Cystinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000975-33 Sponsor Protocol Number: RDCRN_RKSC_6412 Start Date*: 2013-11-19
    Sponsor Name:Landspitali - The National University Hospital of Iceland
    Full Title: Novel Assays for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites - Rare Diseases Clinical Research Network Protocol Version 1
    Medical condition: Adenine phosphoribosyltransferase deficiency
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2018-004014-17 Sponsor Protocol Number: ALN-GO1-004 Start Date*: 2019-03-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1
    Medical condition: Primary Hyperoxaluria Type 1 (PH1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000971-18 Sponsor Protocol Number: SynAct-CS003 Start Date*: 2020-05-28
    Sponsor Name:SynAct Pharma ApS
    Full Title: An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered ...
    Medical condition: Idiopathic membranous nephropathy and severe proteinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000799-15 Sponsor Protocol Number: 04-04074 Start Date*: 2004-09-09
    Sponsor Name:Aker University Hospital
    Full Title: DOES BENFOTIAMINE SUPPLEMENTATION REDUCE SERUM LEVELS OF ADVANCED GLYCATION END PRODUCTS AND BIOCHEMICAL MARKERS OF VASCULAR DYSFUNCTION IN TYPE 1 DIABETES?
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000165-16 Sponsor Protocol Number: DC2019REGROUP01 Start Date*: 2020-09-16
    Sponsor Name:Amsterdam University Medical Center - location VU Medical Center
    Full Title: A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with ei...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005416-26 Sponsor Protocol Number: ANSWER Start Date*: 2014-06-06
    Sponsor Name:Mario Negri Institute
    Full Title: A Prospective, Randomized, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess The Renal and Humoral Effects of Sevelamer Carbonate in Patients with Chronic Kidney Disease and Residual Protein...
    Medical condition: Chronic Kidney Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000921-29 Sponsor Protocol Number: ALLN-177-302 Start Date*: 2019-11-12
    Sponsor Name:Allena Pharmaceuticals, Inc.
    Full Title: Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Double-Blind, Placebo-Controlled Study (URIROX-2)
    Medical condition: Enteric Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PT (Completed) ES (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA